Francisco Marin

Universidad de Murcia

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (16)

Inmaculada Ramírez-Macías

SPAIN

View details

Francesco Santoro

University of Foggia

ITALY

View details

Ibrahim El‐Battrawy

GERMANY

View details

Giuseppe Boriani

ITALY

View details

Garry McDowell

Reader in Clinical Biochemistry

Liverpool John Moores University

UNITED KINGDOM

View details

Eduard Shantsila

Senior Clinical Lecturer

University of Liverpool

UNITED KINGDOM

View details

Marco PROIETTI

Assistant Professor

University of Milan

ITALY

View details

Carina Blomström-Lundqvist

Uppsala University

SWEDEN

View details

Laurent Fauchier

Université de Tours

FRANCE

View details

Ivan J Nuñez-Gil

Universidad Complutense de Madrid

SPAIN

View details

Vanessa Roldan

Associated Professor Hematology

Universidad de Murcia Facultad de Medicina

SPAIN

View details

Manlio Vinciguerra

St. Anne's University Hospital

CZECH REPUBLIC

View details

Stine Krogh Venø

Aalborg University

DENMARK

View details

Radosław Lenarczyk

professor

Medical University of Silesia

POLAND

View details

Esteban Orenes-Piñero

Universidad de Murcia

SPAIN

View details

Manuel Anguita Sánchez

Universidad de Córdoba

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Francisco Marin

Research Interests

Explore related searches

Contact this professor

Articles (11)

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.

Patient selection, peri-procedural management, and ablation techniques for catheter ablation of atrial fibrillation: an EHRA survey

Factors Associated with Progression of Atrial Fibrillation and Impact on All-Cause Mortality in a Cohort of European Patients

Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)

Contemporary management of atrial fibrillation and the predicted vs. absolute risk of ischaemic stroke despite treatment: a report from ESC-EHRA EORP-AF Long-Term General Registry

Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis

Novel insights in the relationship of gut microbiota and coronary artery diseases

Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.

Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.

MiR-146a Contributes to Thromboinflammation and Recurrence in Young Patients with Acute Myocardial Infarction

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists

Collaborators (16)

Inmaculada Ramírez-Macías

Francesco Santoro

Ibrahim El‐Battrawy

Giuseppe Boriani

Garry McDowell

Eduard Shantsila

Marco PROIETTI

Carina Blomström-Lundqvist

Laurent Fauchier

Ivan J Nuñez-Gil

Vanessa Roldan

Manlio Vinciguerra

Stine Krogh Venø

Radosław Lenarczyk

Esteban Orenes-Piñero

Manuel Anguita Sánchez

Make your next move.

Francisco Marin

Research Interests

Explore related searches

Contact this professor

Articles (11)

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.

Patient selection, peri-procedural management, and ablation techniques for catheter ablation of atrial fibrillation: an EHRA survey

Factors Associated with Progression of Atrial Fibrillation and Impact on All-Cause Mortality in a Cohort of European Patients

Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)

Contemporary management of atrial fibrillation and the predicted vs. absolute risk of ischaemic stroke despite treatment: a report from ESC-EHRA EORP-AF Long-Term General Registry

Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis

Novel insights in the relationship of gut microbiota and coronary artery diseases

Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.

Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.

MiR-146a Contributes to Thromboinflammation and Recurrence in Young Patients with Acute Myocardial Infarction

Relation of the &lsquo;Atrial Fibrillation Better Care (ABC) Pathway&rsquo; to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists

Collaborators (16)

Inmaculada Ramírez-Macías

Francesco Santoro

Ibrahim El‐Battrawy

Giuseppe Boriani

Garry McDowell

Eduard Shantsila

Marco PROIETTI

Carina Blomström-Lundqvist

Laurent Fauchier

Ivan J Nuñez-Gil

Vanessa Roldan

Manlio Vinciguerra

Stine Krogh Venø

Radosław Lenarczyk

Esteban Orenes-Piñero

Manuel Anguita Sánchez

Make your next move.

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists